Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Filipa Lynce, M.D.

Profile Picture

Universidade Nova, Lisboa, PortugalMD10/2004

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Pohlmann PR, Graham D, Wu T, Ottaviano Y, Mohebtash M, Kurian S, McNamara D, Lynce F, Warren R, Dilawari A, Rao S, Mainor C, Swanson N, Tan M, Isaacs C, Swain SM. HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane. Breast Cancer Res Treat. 2022 Dec; 196(3):571-581. PMID: 36280642; PMCID: PMC9633499.
    Citations:    Fields:    Translation:CTClinical Trials
  2. Warren LEG, Niman SM, Remolano MC, Landry JM, Nakhlis F, Bellon JR, Aizer AA, Lin NU, Tolaney SM, Regan MM, Overmoyer BA, Lynce F. Incidence, characteristics, and management of central nervous system metastases in patients with inflammatory breast cancer. Cancer. 2022 Dec 01; 128(23):4085-4094. PMID: 36210737.
    Citations:    Fields:    
  3. Schlam I, Tarantino P, Morganti S, Lynce F, Trapani D, Mayer EL, Garrido-Castro AC, Waks A, Tolaney SM. Emerging Targeted Therapies for Early Breast Cancer. Drugs. 2022 Sep; 82(14):1437-1451. PMID: 36207645.
    Citations:    Fields:    
  4. Tarantino P, Niman SM, Erick TK, Priedigkeit N, Harrison BT, Giordano A, Nakhlis F, Bellon JR, Parker T, Strauss S, Jin Q, King TA, Overmoyer BA, Curigliano G, Regan MM, Tolaney SM, Lynce F. HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications. Eur J Cancer. 2022 10; 174:277-286. PMID: 36116830.
    Citations:    Fields:    
  5. Heeke AL, Elliott A, Feldman R, O'Connor HF, Pohlmann PR, Lynce F, Swain SM, Nunes MR, Magee D, Oberley MJ, Swenson J, Vidal G, Isaacs C, Schwartzberg L, Korn WM, Tan AR. Molecular characterization of ESR1 variants in breast cancer. Breast Cancer Res Treat. 2022 Nov; 196(2):279-289. PMID: 36125660.
    Citations:    Fields:    
  6. Pernas S, Guerriero JL, Naumenko S, Goel S, Regan MM, Hu J, Harrison BT, Lynce F, Lin NU, Partridge A, Morikawa A, Hutchinson J, Mittendorf EA, Sokolov A, Overmoyer B. Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer. Ther Adv Med Oncol. 2022; 14:17588359221113269. PMID: 35923923; PMCID: PMC9340890.
  7. Schlam I, Nunes R, Lynce F. Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer. Onco Targets Ther. 2022; 15:471-478. PMID: 35509453; PMCID: PMC9059982.
  8. Conley CC, McIntyre M, Pensak NA, Lynce F, Graham D, Ismail-Khan R, Lopez K, Vadaparampil ST, O'Neill SC. Barriers and facilitators to taking CDK4/6 inhibitors among patients with metastatic breast cancer: a qualitative study. Breast Cancer Res Treat. 2022 Apr; 192(2):385-399. PMID: 34997364; PMCID: PMC8930642.
    Citations:    Fields:    Translation:Humans
  9. Schneider BP, Jiang G, Ballinger TJ, Shen F, Chitambar C, Nanda R, Falkson C, Lynce FC, Gallagher C, Isaacs C, Blaya M, Paplomata E, Walling R, Daily K, Mahtani R, Thompson MA, Graham R, Cooper ME, Pavlick DC, Albacker LA, Gregg J, Solzak JP, Chen YH, Bales CL, Cantor E, Hancock BA, Kassem N, Helft P, O'Neil B, Storniolo AMV, Badve S, Miller KD, Radovich M. BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. J Clin Oncol. 2022 02 01; 40(4):345-355. PMID: 34910554.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  10. Sardesai SD, Thomas A, Gallagher C, Lynce F, Ottaviano YL, Ballinger TJ, Schneider BP, Storniolo AM, Bauchle A, Althouse SK, Perkins SM, Masters AR, Stratford RE, Dong Z, Liu JY, Zhang JT, Miller KD. Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC. Clin Cancer Res. 2021 11 01; 27(21):5810-5817. PMID: 34400413.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  11. Lynce F, Blackburn MJ, Zhuo R, Gallagher C, Hahn OM, Abu-Khalaf M, Mohebtash M, Wu T, Pohlmann PR, Dilawari A, Tiwari SR, Chitalia A, Warren R, Tan M, Shajahan-Haq AN, Isaacs C. Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer. Cancer. 2021 10 01; 127(19):3622-3630. PMID: 34157782.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  12. Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021 04 22; 384(16):1529-1541. PMID: 33882206.
    Citations: 123     Fields:    Translation:HumansCTClinical Trials
  13. Lynce F, Nunes R. Role of Platinums in Triple-Negative Breast Cancer. Curr Oncol Rep. 2021 03 22; 23(5):50. PMID: 33754211.
    Citations: 7     Fields:    Translation:Humans
  14. Lynce F, Williams JT, Regan MM, Bunnell CA, Freedman RA, Tolaney SM, Chen WY, Mayer EL, Partridge AH, Winer EP, Overmoyer B. Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer. Cancer Chemother Pharmacol. 2021 05; 87(5):673-679. PMID: 33585999.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  15. Khoury K, Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, Gallagher C, Pohlmann PR, Nunes R, Herbolsheimer P, Warren R, Srichai MB, Hofmeyer M, Asch F, Tan M, Isaacs C, Swain SM. Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function. Breast Cancer Res Treat. 2021 Feb; 185(3):863-868. PMID: 33400034; PMCID: PMC8207895.
    Citations: 2     Fields:    Translation:Humans
  16. Lynce F, Schlam I, Geng X, Peshkin BN, Friedman S, Dutil J, Nahleh Z, Campos C, Ricker C, Rodriguez P, Denduluri N, Ahn J, Isaacs C, Graves KD. BRCA1/2 mutations and risk-reducing bilateral salpingo-oophorectomy among Latinas: The UPTAKE study. J Genet Couns. 2021 04; 30(2):383-393. PMID: 33010199.
    Citations:    Fields:    Translation:Humans
  17. Radovich M, Jiang G, Hancock BA, Chitambar C, Nanda R, Falkson C, Lynce FC, Gallagher C, Isaacs C, Blaya M, Paplomata E, Walling R, Daily K, Mahtani R, Thompson MA, Graham R, Cooper ME, Pavlick DC, Albacker LA, Gregg J, Solzak JP, Chen YH, Bales CL, Cantor E, Shen F, Storniolo AMV, Badve S, Ballinger TJ, Chang CL, Zhong Y, Savran C, Miller KD, Schneider BP. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial. JAMA Oncol. 2020 09 01; 6(9):1410-1415. PMID: 32644110.
    Citations: 61     Fields:    Translation:HumansCellsCTClinical Trials
  18. Khoury K, Tan AR, Elliott A, Xiu J, Gatalica Z, Heeke AL, Isaacs C, Pohlmann PR, Schwartzberg LS, Simon M, Korn WM, Swain SM, Lynce F. Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer. Front Oncol. 2020; 10:1475. PMID: 32983983; PMCID: PMC7489343.
    Citations: 5     
  19. Heeke AL, Xiu J, Elliott A, Korn WM, Lynce F, Pohlmann PR, Isaacs C, Swain SM, Vidal G, Schwartzberg LS, Tan AR. Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway. Breast Cancer Res Treat. 2020 Nov; 184(2):265-275. PMID: 32776290.
    Citations: 10     Fields:    Translation:Humans
  20. Barac A, Isaacs C, M Shara N, Lynce F, Desale S, Haynes K, Potosky AL. Trends in the Use of Cardiac Imaging for Women with Newly Diagnosed Breast Cancer. J Cardiovasc Transl Res. 2020 06; 13(3):478-489. PMID: 32458402.
    Citations:    Fields:    Translation:Humans
  21. Lynce F, Wang H, Petricoin EF, Pohlmann PR, Smaglo B, Hwang J, He AR, Subramaniam DS, Deeken J, Marshall J, Pishvaian MJ. A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies. Cancer Chemother Pharmacol. 2019 11; 84(5):1145-1151. PMID: 31538230.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  22. Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, Wahner-Hendrickson AE, Forero A, Anders C, Wulf GM, Dillon P, Lynce F, Zarwan C, Erban JK, Zhou Y, Buerstatte N, Graham JR, Arora S, Dezube BJ, Telli ML. Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. JAMA Oncol. 2019 Aug 01; 5(8):1132-1140. PMID: 31194225; PMCID: PMC6567845.
    Citations: 105     Fields:    
  23. Richter LA, Han J, Bradley S, Lynce FC, Willey SC, Tefera E, Pollack CE. Topical estrogen prescribing patterns for urogenital atrophy among women with breast cancer: results of a national provider survey. Menopause. 2019 07; 26(7):714-719. PMID: 30939535.
    Citations: 1     Fields:    Translation:Humans
  24. Barac A, Blaes A, Lynce F. Lessons From Primary Cardiac Prevention Trials During Trastuzumab Therapy: End of One Size Fits All. J Am Coll Cardiol. 2019 06 11; 73(22):2869-2871. PMID: 31171093.
    Citations: 4     Fields:    Translation:Humans
  25. Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, Gallagher C, Pohlmann PR, Nunes R, Herbolsheimer P, Warren R, Srichai MB, Hofmeyer M, Cunningham A, Timothee P, Asch FM, Shajahan-Haq A, Tan MT, Isaacs C, Swain SM. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat. 2019 Jun; 175(3):595-603. PMID: 30852761; PMCID: PMC6534513.
    Citations: 53     Fields:    Translation:HumansCTClinical Trials
  26. Barish R, Lynce F, Unger K, Barac A. Management of Cardiovascular Disease in Women With Breast Cancer. Circulation. 2019 02 19; 139(8):1110-1120. PMID: 30779651.
    Citations: 19     Fields:    Translation:HumansPHPublic Health
  27. Boughey JC, Alvarado MD, Lancaster RB, Symmans WF, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Goodellas C, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ. Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. NPJ Breast Cancer. 2019; 5:2. PMID: 30675512; PMCID: PMC6315027.
  28. Heeke A, Nunes MR, Lynce F. Bone-Modifying Agents in Early-Stage and Advanced Breast Cancer. Curr Breast Cancer Rep. 2018; 10(4):241-250. PMID: 30581537; PMCID: PMC6276066.
    Citations: 8     
  29. Boughey JC, Alvarado MD, Lancaster RB, Fraser Symmans W, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ. Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. NPJ Breast Cancer. 2018; 4:26. PMID: 30131975; PMCID: PMC6098077.
    Citations: 4     
  30. Dang CT, Blaes A, Lynce F, Swain SM, Dent S. Left Ventricular Ejection Fraction Monitoring Adherence Rates: Why So Low? JACC Cardiovasc Imaging. 2018 08; 11(8):1094-1097. PMID: 30092968.
    Citations: 1     Fields:    Translation:Humans
  31. Heeke AL, Pishvaian MJ, Lynce F, Xiu J, Brody JR, Chen WJ, Baker TM, Marshall JL, Isaacs C. Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. JCO Precis Oncol. 2018; 2018. PMID: 30234181; PMCID: PMC6139373.
    Citations: 120     Fields:    
  32. Lynce F, Shajahan-Haq AN, Swain SM. CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities. Pharmacol Ther. 2018 11; 191:65-73. PMID: 29933034; PMCID: PMC6533626.
    Citations: 19     Fields:    Translation:HumansAnimals
  33. Lynce F, Saleh M, Shajahan-Haq A, Gallagher C, Dilawari A, Hahn O, Abu-Khalaf M, Cai L, Pohlmann P, Mohebtash M, Kamugisha L, Isaacs C. PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer. Contemp Clin Trials Commun. 2018 Jun; 10:190-192. PMID: 30009277; PMCID: PMC6042467.
    Citations: 1     
  34. Heath EI, Lynce F, Xiu J, Ellerbrock A, Reddy SK, Obeid E, Liu SV, Bollig-Fischer A, Separovic D, Vanderwalde A. Racial Disparities in the Molecular Landscape of Cancer. Anticancer Res. 2018 04; 38(4):2235-2240. PMID: 29599344; PMCID: PMC6123828.
    Citations: 17     Fields:    Translation:Humans
  35. Lynce F, Blackburn MJ, Cai L, Wang H, Rubinstein L, Harris P, Isaacs C, Pohlmann PR. Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials. Breast Cancer Res Treat. 2018 Feb; 168(1):35-41. PMID: 29119354; PMCID: PMC5940334.
    Citations: 5     Fields:    Translation:Humans
  36. Robinson BN, Newman AF, Tefera E, Herbolsheimer P, Nunes R, Gallagher C, Randolph-Jackson P, Omogbehin A, Dilawari A, Pohlmann PR, Mohebtash M, Lee Y, Ottaviano Y, Mohapatra A, Lynce F, Brown R, Mete M, Swain SM. Video intervention increases participation of black breast cancer patients in therapeutic trials. NPJ Breast Cancer. 2017; 3:36. PMID: 28944289; PMCID: PMC5603544.
    Citations: 7     
  37. Tsai HT, Isaacs C, Lynce FC, O'Neill SC, Liu C, Schwartz MD, Selvam N, Zhou Y, Potosky AL. Initiation of Trastuzumab by Women Younger Than 64 Years for Adjuvant Treatment of Stage I-III Breast Cancer. J Natl Compr Canc Netw. 2017 05; 15(5):601-607. PMID: 28476740.
    Citations: 2     Fields:    Translation:Humans
  38. O'Neill SC, Isaacs C, Lynce F, Graham DM, Chao C, Sheppard VB, Zhou Y, Liu C, Selvam N, Schwartz MD, Potosky AL. Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65. Breast Cancer Res. 2017 03 31; 19(1):45. PMID: 28359319; PMCID: PMC5374604.
    Citations: 4     Fields:    Translation:Humans
  39. Lynce F, Barac A, Tan MT, Asch FM, Smith KL, Dang C, Isaacs C, Swain SM. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. Oncologist. 2017 05; 22(5):518-525. PMID: 28314836.
    Citations: 18     Fields:    Translation:HumansCTClinical Trials
  40. Lynce F, Graves KD, Jandorf L, Ricker C, Castro E, Moreno L, Augusto B, Fejerman L, Vadaparampil ST. Genomic Disparities in Breast Cancer Among Latinas. Cancer Control. 2016 Oct; 23(4):359-372. PMID: 27842325; PMCID: PMC5160045.
    Citations: 22     Fields:    Translation:Humans
  41. Lynce F, Isaacs C. Population-Based BRCA1/2 Testing in Ashkenazi Jews: Ready for Prime Time. J Natl Compr Canc Netw. 2016 06; 14(6):809-12. PMID: 27283172.
    Citations: 2     Fields:    Translation:Humans
  42. Barac A, Lynce F, Smith KL, Mete M, Shara NM, Asch FM, Nardacci MP, Wray L, Herbolsheimer P, Nunes RA, Swain SM, Warren R, Peshkin BN, Isaacs C. Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines. Breast Cancer Res Treat. 2016 Jan; 155(2):285-93. PMID: 26749359.
    Citations: 8     Fields:    Translation:Humans
  43. Lynce F, Isaacs C. How Far Do We Go With Genetic Evaluation? Gene, Panel, and Tumor Testing. Am Soc Clin Oncol Educ Book. 2016; 35:e72-8. PMID: 27249773.
    Citations: 19     Fields:    Translation:HumansCells
  44. Lynce F, Graves K. Differences in Uptake of Risk Reduction Strategies Among Underserved Populations. EBioMedicine. 2015 Nov; 2(11):1598-9. PMID: 26870783; PMCID: PMC4740341.
    Citations:    Fields:    Translation:Humans
  45. Lynce F, Smith KL, Stein J, DeMarco T, Wang Y, Wang H, Fries M, Peshkin BN, Isaacs C. Deleterious BRCA1/2 mutations in an urban population of Black women. Breast Cancer Res Treat. 2015 Aug; 153(1):201-9. PMID: 26250392; PMCID: PMC5963698.
    Citations: 11     Fields:    Translation:HumansPHPublic Health
  46. Lynce F, Swain SM. Pertuzumab for the treatment of breast cancer. Cancer Invest. 2014 Oct; 32(8):430-8. PMID: 24921704.
    Citations: 5     Fields:    Translation:HumansAnimals
  47. Lynce F, Yin F, Alcorn K, Malkovska V. Post-transfusion purpura in an African-American man due to human platelet antigen-5b alloantibody: a case report. J Med Case Rep. 2012 Dec 12; 6:420. PMID: 23234542.
    Citations: 2     Fields:    
  48. Lynce F, Swain SM. Avastin withdrawal symptoms. Expert Opin Pharmacother. 2012 Feb; 13(3):293-8. PMID: 22263961.
    Citations:    Fields:    Translation:HumansAnimals
  49. Lynce F, Pehlivanova M, Catlett J, Malkovska V. Obesity in adult lymphoma survivors. Leuk Lymphoma. 2012 Apr; 53(4):569-74. PMID: 21888618.
    Citations: 5     Fields:    Translation:Humans
  50. Lynce F, Swain SM. First, do no harm. Onkologie. 2008 Oct; 31(10):511-2. PMID: 18854649.
    Citations:    Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Lynce's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (159)
Co-Authors (24)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.